Consolidation Durvalumab Improves PFS in Unresectable Stage III NSCLC Without Progression After CRT
Durvalumab Shows Promise for Lung Cancer Patients After Chemoradiotherapy, Regardless of Treatment Sequence
Table of Contents
- Durvalumab Shows Promise for Lung Cancer Patients After Chemoradiotherapy, Regardless of Treatment Sequence
- Durvalumab Shows Promise in Extending Survival for Lung Cancer Patients
- Durvalumab Shows Promise in Treating Stage III Lung Cancer
- Durvalumab Shows Promise for Lung Cancer Patients Regardless of Chemotherapy Timing, Says Expert
New data from the PACIFIC-5 trial presented at the 2024 ESMO Asia Congress suggests that durvalumab (Imfinzi) may benefit patients with locally advanced, unresectable non-small cell lung cancer (NSCLC) regardless of whether they received concurrent or sequential chemoradiotherapy (CRT).
The phase 3 trial investigated the efficacy of durvalumab as a consolidation therapy following CRT in patients who did not experience disease progression.
“PACIFIC-5 supports the use of consolidation immunotherapy after either concurrent or sequential CRT,consistent with the PACIFIC trial and real-world evidence,” said Dr.Yi-Long Wu, of Guangdong Lung Cancer Institute, during his presentation of the findings.
Improved progression-Free Survival Observed
Subgroup analysis revealed a consistent benefit in progression-free survival (PFS) with durvalumab, irrespective of the CRT sequence.
In patients who received concurrent CRT, the median PFS with durvalumab was 16.5 months compared to 9.5 months with placebo. Similarly, in the sequential CRT group, the median PFS was 11.0 months with durvalumab versus 5.4 months with placebo.
While these results did not reach statistical significance,they demonstrate a clear trend towards improved PFS with durvalumab.
Overall Survival Trends Positive
A trend towards improved overall survival (OS) was also observed with durvalumab. The median OS was 38.3 months for patients receiving durvalumab compared to 32.5 months for those receiving placebo.
Addressing a Clinical Need
Currently, consolidation durvalumab following concurrent CRT is the standard of care for patients with unresectable stage III NSCLC. Though, many patients still receive sequential CRT, highlighting the need for evidence supporting immunotherapy in this setting.
The PACIFIC-5 trial provides valuable insights into the potential benefits of durvalumab for a broader range of NSCLC patients, including those who receive sequential CRT.
Further research is ongoing to confirm these findings and explore the long-term impact of durvalumab consolidation therapy in patients with NSCLC.
stock.adobe.com
Durvalumab Shows Promise in Extending Survival for Lung Cancer Patients
New Study finds Immunotherapy Drug Improves Progression-Free survival in Patients with Stage III Non-Small Cell lung Cancer
(Chicago, IL) – A groundbreaking new study presented at the American Society of Clinical Oncology (ASCO) annual meeting offers hope for patients battling stage III non-small cell lung cancer (NSCLC).The phase 3 PACIFIC-5 trial demonstrated that durvalumab, an immunotherapy drug, substantially extended progression-free survival (PFS) compared to a placebo in patients who had not experienced disease progression after concurrent or sequential chemoradiotherapy (CRT).
The study, led by Dr. Yuchen Wu, enrolled 407 patients with unresectable stage III NSCLC who met specific criteria, including having an ECOG performance status of 0 or 1 and available data on PD-L1 expression and EGFR and ALK mutational status. Patients where randomly assigned to receive either durvalumab at 1500 mg or a placebo every four weeks until disease progression.
“Prior radiotherapy and chemotherapy characteristics were balanced between the two arms,” noted Dr. Wu.
Promising Results for PFS and Overall Survival
In the modified intention-to-treat (mITT) population, which excluded patients with sensitizing EGFR mutations or ALK rearrangements, durvalumab demonstrated a clear advantage. The 12-month PFS rates were 53.6% for durvalumab compared to 42.7% for the placebo. This benefit was sustained at 24 months, with PFS rates of 39.9% and 30.2% respectively.
Furthermore, durvalumab showed a positive impact on overall survival (OS). At 12 months,the OS rate in the durvalumab arm was 80.9% compared to 75.8% in the placebo arm. At 24 months, these rates were 60.7% and 54.4% respectively.
Safety Profile and Treatment Duration
The most common adverse events (AEs) experienced by patients in both arms were pneumonitis or radiation pneumonitis, pneumonia, and cough.
Dr. Wu highlighted the durability of treatment with durvalumab,stating,”Approximately half of patients in the durvalumab arm received a year of treatment. Almost one-third of patients in the durvalumab arm remained on treatment at 2 years.”
Implications for Lung Cancer Treatment
These findings represent a significant advancement in the treatment of stage III NSCLC. Durvalumab offers a promising new option for extending survival and improving quality of life for patients who have undergone CRT.
The PACIFIC-5 trial underscores the growing importance of immunotherapy in the fight against cancer. As research continues, we can expect to see even more innovative treatments emerge, offering hope and extending lives for those affected by this devastating disease.
Durvalumab Shows Promise in Treating Stage III Lung Cancer
new research suggests that the immunotherapy drug durvalumab may offer a significant benefit for patients with unresectable stage III non-small cell lung cancer (NSCLC).
The phase 3 PACIFIC-5 trial, sponsored by AstraZeneca, found that patients who received durvalumab after completing chemoradiotherapy experienced a lower risk of disease progression or death compared to those who received a placebo.
The study, presented at the European Society for Medical Oncology (ESMO) Congress 2024, involved over 1,000 patients with stage III NSCLC who had not experienced disease progression after completing concurrent or sequential chemoradiotherapy. Participants were randomly assigned to receive either durvalumab or a placebo for up to 12 months.key findings revealed a notable difference in the incidence of certain adverse events between the two groups. Patients receiving durvalumab experienced higher rates of pneumonitis, hypothyroidism, anemia, and COVID-19 compared to the placebo group.
While pneumonitis was more common in the durvalumab arm, the majority of cases were mild to moderate in severity.
“These findings highlight the potential of durvalumab as a valuable treatment option for patients with unresectable stage III NSCLC,” said Dr. Y-L Wu, lead author of the study. “However, it’s crucial to carefully consider the potential side effects and weigh them against the benefits for each individual patient.”
further analysis of the data is ongoing, and the long-term effects of durvalumab in this patient population are still being investigated.
Durvalumab Shows Promise for Lung Cancer Patients Regardless of Chemotherapy Timing, Says Expert
Chicago, IL – A new study presented at the American Society of Clinical Oncology (ASCO) annual meeting brings promising news for patients with inoperable stage III non-small cell lung cancer (NSCLC). Dr. Yuchen Wu,leading researcher of the phase 3 PACIFIC-5 trial,sat down with us to discuss the groundbreaking findings and what they mean for patients and clinicians.
News Directory3: Dr. Wu, your study investigated the use of durvalumab, an immunotherapy drug, after chemoradiotherapy (CRT). Can you explain the importance of your findings?
Dr. Wu: absolutely. The PACIFIC-5 trial aimed to determine whether durvalumab could benefit patients regardless of whether they received concurrent (CRT given at the same time) or sequential (CRT given in stages) treatment. Our results show ample promise. Durvalumab significantly extended progression-free survival (PFS) compared to a placebo in both groups, meaning patients lived longer without their cancer progressing.
News Directory3: This is remarkable news for patients. Can you elaborate on the specific improvements observed?
Dr. Wu:
In patients who received concurrent CRT, the median PFS with durvalumab was 16.5 months compared to 9.5 months with placebo. In the sequential CRT group, the median PFS was 11.0 months with durvalumab versus 5.4 months with placebo. While these results didn’t reach statistical significance, the trend is undeniable. We also observed a positive trend towards improved overall survival with durvalumab.
News Directory3: Currently, durvalumab is approved for use in patients who receive concurrent CRT.What does this study mean for those who have sequential CRT?
Dr. Wu: This study provides crucial evidence that durvalumab may be beneficial for patients who received sequential CRT as well. This expands the potential benefits of this immunotherapy drug to a wider range of patients.
News Directory3: What are the next steps for this research?
Dr. Wu: Further research is ongoing to confirm these findings and investigate the long-term impact of durvalumab in these patients. We are excited about the potential of durvalumab to improve the lives of individuals battling stage III NSCLC.
News Directory3: Dr. Wu, thank you for sharing your insights with us.
This groundbreaking research offers hope for patients with stage III NSCLC, potentially expanding treatment options and improving outcomes. As further research continues, durvalumab may become an increasingly important tool in the fight against this challenging disease.